logo
How it worksCoursesResearch CommunitiesBenefitsAbout Us
Schedule Demo
Learn Before

  • Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion

  • Outcomes among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion

Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion

BCRSS scores decreased overall for all patients given TCZ transfusion, showing clinical improvements, but not necessarily statistical significance.

Image 0

0

1

6 years ago

Contributors are:

Lisa Mayer
Lisa Mayer
🏆 3

Who are from:

University of Michigan - Ann Arbor
University of Michigan - Ann Arbor
🏆 3

References

Tags

SARS-CoV-2 (COVID-19)

Biomedical Sciences

Related

  • Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion

  • Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion

Learn After

  • Brescia COVID-19 Respiratory Severity Scale (BCRSS)